Crossmark Global Holdings Inc. acquired a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,270 shares of the life sciences company’s stock, valued at approximately $619,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Integra LifeSciences Holdings Corporation by 6.2% in the 2nd quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock valued at $440,690,000 after acquiring an additional 468,678 shares during the period. Capital Research Global Investors increased its holdings in shares of Integra LifeSciences Holdings Corporation by 227.0% in the 2nd quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after acquiring an additional 2,705,488 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Integra LifeSciences Holdings Corporation in the 2nd quarter valued at $112,068,000. Eagle Asset Management Inc. increased its holdings in shares of Integra LifeSciences Holdings Corporation by 39.0% in the 2nd quarter. Eagle Asset Management Inc. now owns 1,647,018 shares of the life sciences company’s stock valued at $89,778,000 after acquiring an additional 461,977 shares during the period. Finally, State Street Corp increased its holdings in shares of Integra LifeSciences Holdings Corporation by 5.2% in the 2nd quarter. State Street Corp now owns 1,575,125 shares of the life sciences company’s stock valued at $85,860,000 after acquiring an additional 78,082 shares during the period. Institutional investors own 83.60% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (IART) opened at $47.48 on Friday. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.39 and a current ratio of 4.49. The company has a market capitalization of $3,665.68, a PE ratio of 25.81, a price-to-earnings-growth ratio of 2.03 and a beta of 0.64.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences Holdings Corporation had a return on equity of 16.35% and a net margin of 4.52%. The firm had revenue of $278.83 million for the quarter, compared to analyst estimates of $286.00 million. During the same period in the prior year, the firm posted $0.93 EPS. The business’s revenue was up 11.4% compared to the same quarter last year. equities analysts forecast that Integra LifeSciences Holdings Corporation will post 1.87 earnings per share for the current year.

A number of brokerages have recently issued reports on IART. BidaskClub downgraded Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Barclays PLC reiterated an “equal weight” rating and issued a $53.00 price target (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a report on Tuesday, September 12th. Jefferies Group LLC reissued a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $60.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research report on Monday, September 18th. Finally, Zacks Investment Research cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $53.82.

In other news, Director Barbara B. Hill purchased 10,768 shares of the stock in a transaction on Tuesday, October 31st. The stock was bought at an average price of $46.66 per share, with a total value of $502,434.88. Following the transaction, the director now owns 55,540 shares in the company, valued at approximately $2,591,496.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Richard D. Gorelick sold 1,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the sale, the vice president now directly owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The disclosure for this sale can be found here. Insiders own 21.50% of the company’s stock.

WARNING: “Crossmark Global Holdings Inc. Invests $619,000 in Integra LifeSciences Holdings Corporation (IART) Stock” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/crossmark-global-holdings-inc-invests-619000-in-integra-lifesciences-holdings-corporation-iart-stock/1709061.html.

Integra LifeSciences Holdings Corporation Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.